Back to search

Peptide record

TPDB41509

LA3IK-SCR Anticancer standard
6 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41509
LA3IK-SCR
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 6-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-LAKAVI-NH2
Physicochemical Analysis
C29H55N7O7
RNDCEQGHMFPSTWY
A
613.80
10.10
1
0
5
+1
-0.15
2.033
211.67
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
1
L
1
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
6
C29H55N7O7
613.80
10.10
+1
-0.15
2.033
Amidation
L
Linear
Acetylation
Anticancer
Migration and invasion enhancer 1 (MIEN1)
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 243 ± 8.16 µM
Anticancer
243

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 133 ± 9.52 µM
Anticancer
133

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024
Evidence 3 Activity

Activity

IC50
IC50 = 319 ± 13.64 µM
Anticancer
319

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024
Evidence 4 Activity

Activity

IC50
IC50 = 351.76 ± 7.18 µM
Anticancer
351.76

Target

Prostate Cancer
DU-145
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024